Bortezomib-Induced Bilateral Eye Swelling and Cutaneous Adverse Reaction in a Patient with Plasma Cell Leukemia—A Case Report  

作　　者：Azeezat Ariwoola Ehab A. M. Elagab Tahira Fardous Saburi Oyewale Sara Parisi Heather Williams Amal M. Shediwah Islam A. Mahmoud Ratesh Khillan Azeezat Ariwoola;Ehab A. M. Elagab;Tahira Fardous;Saburi Oyewale;Sara Parisi;Heather Williams;Amal M. Shediwah;Islam A. Mahmoud;Ratesh Khillan(School of Public Health, Rutgers University, New Brunswick, USA;Department of Pathology, College of Medicine, Najran University, Najran, Saudi Arabia;Brooklyn Cancer Care, New York, USA;Department of Surgery, University of Ilorin Teaching Hospital, Ilorin, Nigeria;Shiqaq Primary Health Center MOH, Al Darb, Saudi Arabia;SUNY Downstate University Hospital, New York, USA)

机构地区：[1]School of Public Health, Rutgers University, New Brunswick, USA [2]Department of Pathology, College of Medicine, Najran University, Najran, Saudi Arabia [3]Brooklyn Cancer Care, New York, USA [4]Department of Surgery, University of Ilorin Teaching Hospital, Ilorin, Nigeria [5]Shiqaq Primary Health Center MOH, Al Darb, Saudi Arabia [6]SUNY Downstate University Hospital, New York, USA

出　　处：《Case Reports in Clinical Medicine》2023年第11期452-456,共5页临床医学病理报告（英文）

摘　　要：Bortezomib, a proteasome inhibitor, is an established therapy against plasma cell leukemia—a variant of plasma cell dyscrasias. Its most frequent side effects have been listed as peripheral neuropathy, neuropathic pain, thrombocytopenia, and gastrointestinal problems. Allergic skin reaction is a rarely documented side effect in patients receiving bortezomib-based chemotherapy. A combination therapy consisting of intravenous bortezomib, oral Revlimid tablets, and oral dexamethasone tablets has been prescribed for the patient after his recent diagnosis of plasma cell leukemia. While receiving his third treatment cycle, he developed an allergic reaction (skin rash) involving the neck, and wrists, and mild bilateral eye swelling. The infusion was stopped immediately and then ciprofloxacin ophthalmic solution and oral diphenhydramine 25 mg were prescribed to the patient with significant improvement in his clinical condition. He was temporarily taken off bortezomib. At a follow-up visit a week later, a significant improvement was noticed in his condition. Rash had reduced on neck and wrists, and eye swelling had reduced as well. As of the time of writing this case report, he has been temporarily taken off bortezomib, but other medications in the treatment regimen were continued as prescribed.Bortezomib, a proteasome inhibitor, is an established therapy against plasma cell leukemia—a variant of plasma cell dyscrasias. Its most frequent side effects have been listed as peripheral neuropathy, neuropathic pain, thrombocytopenia, and gastrointestinal problems. Allergic skin reaction is a rarely documented side effect in patients receiving bortezomib-based chemotherapy. A combination therapy consisting of intravenous bortezomib, oral Revlimid tablets, and oral dexamethasone tablets has been prescribed for the patient after his recent diagnosis of plasma cell leukemia. While receiving his third treatment cycle, he developed an allergic reaction (skin rash) involving the neck, and wrists, and mild bilateral eye swelling. The infusion was stopped immediately and then ciprofloxacin ophthalmic solution and oral diphenhydramine 25 mg were prescribed to the patient with significant improvement in his clinical condition. He was temporarily taken off bortezomib. At a follow-up visit a week later, a significant improvement was noticed in his condition. Rash had reduced on neck and wrists, and eye swelling had reduced as well. As of the time of writing this case report, he has been temporarily taken off bortezomib, but other medications in the treatment regimen were continued as prescribed.

关 键 词：Plasma Cell Leukemia HEMATOLOGY BORTEZOMIB CHEMOTHERAPY 

分 类 号：R73[医药卫生—肿瘤]